Holen Sie sich die Stockscreener-App
11.05
0.36%
-0.04
Schlusskurs vom Vortag:
$11.09
Offen:
$11.1
24-Stunden-Volumen:
79,842
Relative Volume:
1.00
Marktkapitalisierung:
$180.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.82M
KGV:
-0.4318
EPS:
-25.5891
Netto-Cashflow:
$-66.04M
1W Leistung:
-3.91%
1M Leistung:
-6.36%
6M Leistung:
+30.00%
1J Leistung:
+134.11%
1-Tages-Spanne:
$10.90
$11.15
1-Wochen-Bereich:
$10.90
$11.99
52-Wochen-Spanne:
$4.05
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Vergleichen Sie ELTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
11.05 | 181.19M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
Using R and stats models for Elicio Therapeutics Inc. forecasting2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Applying Elliott Wave Theory to Elicio Therapeutics Inc.July 2025 Trends & Technical Analysis for Trade Confirmation - newser.com
How moving averages guide Elicio Therapeutics Inc. tradingJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - newser.com
What technical models suggest about Elicio Therapeutics Inc.’s comeback2025 Risk Factors & Expert Approved Momentum Ideas - newser.com
Is Elicio Therapeutics Inc. still worth holding after the dip2025 Market Outlook & AI Forecasted Entry/Exit Points - newser.com
How to use a screener to detect Elicio Therapeutics Inc. breakouts2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Is Elicio Therapeutics Inc. building a consolidation baseWeekly Trend Report & Daily Profit Focused Stock Screening - newser.com
Multi factor analysis applied to Elicio Therapeutics Inc.IPO Watch & Daily Profit Maximizing Tips - newser.com
How sentiment analysis helps forecast Elicio Therapeutics Inc.Quarterly Risk Review & Free Real-Time Market Sentiment Alerts - newser.com
Elicio Therapeutics Hits New 52-Week High of $12.61 - Markets Mojo
ETF Watch: Can Elicio Therapeutics Inc lead its sector in growth2025 Short Interest & Community Verified Swing Trade Signals - خودرو بانک
Will earnings trigger a reversal in Elicio Therapeutics Inc.2025 Macro Impact & Daily Entry Point Trade Alerts - newser.com
Retail Surge: Can TOON expand into new marketsJuly 2025 Spike Watch & Detailed Earnings Play Alerts - khodrobank.com
Technical analysis overview for Elicio Therapeutics Inc. stockMarket Risk Report & Smart Investment Allocation Tips - newser.com
Top chart patterns to watch in Elicio Therapeutics Inc.July 2025 Recap & AI Based Trade Execution Alerts - newser.com
Smart Money: Is Elicio Therapeutics Inc stock suitable for long term investingWatch List & Free Weekly Watchlist of Top Performers - خودرو بانک
Elicio Therapeutics reports inducement grants - TipRanks
Is Elicio Therapeutics Inc. showing signs of accumulationJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
Published on: 2025-09-18 22:03:11 - newser.com
Technical signs of recovery in Elicio Therapeutics Inc.Jobs Report & Growth Oriented Trading Recommendations - newser.com
Rate Hike: Whats next for Elicio Therapeutics Inc stockTrade Performance Summary & High Accuracy Swing Trade Signals - خودرو بانک
Is now a turning point for Elicio Therapeutics Inc.Weekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Is it time to cut losses on Elicio Therapeutics Inc.July 2025 Retail & Accurate Trade Setup Notifications - newser.com
Elicio Therapeutics : AMPLIFY-7P Phase 2 Immunogenicity Data - MarketScreener
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Cancer Vaccine Developer Elicio Therapeutics Awards Stock Options to Expand Research Team - Stock Titan
Risk Check: Does Elicio Therapeutics Inc. have declining or rising EPSMarket Sentiment Review & Fast Exit and Entry Trade Guides - خودرو بانک
Retail Surge: Is Elicio Therapeutics Inc. impacted by rising rates - khodrobank.com
Will Elicio Therapeutics Inc. stock recover after recent dropTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Elicio Therapeutics Announces Promising Phase 2 Vaccine Results - TipRanks
Elicio’s cancer vaccine ELI-002 shows strong immune response in 99% of patients - Investing.com Canada
Elicio Therapeutics Reports 99% mKRAS-Specific T Cell Response in Phase 2 AMPLIFY-7P Trial of ELI-002 Vaccine - Quiver Quantitative
Elicio Therapeutics Reports ELI-002 7P Achieved Robust - GlobeNewswire
145-fold Immune Response Boost: Elicio's Cancer Vaccine Shows Remarkable 99% Success Rate in Phase 2 Study - Stock Titan
Aug Action: Can Elicio Therapeutics Inc. stock double in the next yearJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - خودرو بانک
What are the future prospects of Elicio Therapeutics IncTrade Volume Summary & Technical Pattern Alert System - خودرو بانک
Momentum Shift: What is Elicio Therapeutics Inc.’s book value per shareEarnings Overview Summary & Verified Momentum Stock Watchlist - خودرو بانک
Earnings Update: How do insiders feel about Elicio Therapeutics IncMarket Performance Report & Consistent Growth Equity Picks - خودرو بانک
Published on: 2025-09-15 22:50:51 - newser.com
Growth Review: What are the future prospects of Elicio Therapeutics IncMarket Volume Report & High Conviction Investment Ideas - خودرو بانک
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):